An interventional study of Targeted microwave ablation in Prostate Cancer, sponsored by Koelis. Completed at 5 sites in 2 countries. Open to male participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Koelis · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 509 studies in Prostatic Neoplasms with a site in France — 89 open to participants now, 154 under way, 50 of them phase 3. Prostatic Neoplasms · France.
Among the 509 studies in Prostatic Neoplasms with a site in France, this one is the 287th largest by enrollment of the 405 interventional ones that give a count, is one of 34 that started in 2021, is one of 121 with no phase, and was the 341st registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →89 of the 509 studies in Prostatic Neoplasms with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Austria and 18 more countries
Ages 18+ · Men only
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in France, Germany, Italy and 2 more countries
Ages 18+ · Men only
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+ · Men only
AstraZeneca · Sites in France, United States, Australia and 21 more countries
Ages 18+ · Men only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 45 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
509 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 106 · Phase 3 149 · Phase 4 12
First in 1996; this study’s year is marked. 34 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 185 across the 405 interventional studies, 183 across the 99 observational. Of the 322 that completed or were terminated, 104 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
234 of 509 have an industry lead sponsor. The 10 most frequent:
Koelis is the lead sponsor of 2 studies on the registry; none are open to participants now.
Koelis has 2 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
36 of the studies in Prostatic Neoplasms with a site in France that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT06122584Phase 3ABX advanced biochemical compounds GmbHDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer | 2027-03 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
Add all 36 to your calendar (.ics) → With an account.
Among the 509 studies in Prostatic Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multicenter, prospective, European, single-arm, open-label, 12-month follow-up clinical trial. The purpose of this study is to evaluate the efficacy of a 3D cartography-based targeted microwave ablation for the treatment of the index lesion in patients with intermediate risk prostate cancer.
European and American guidelines recommend several therapeutic alternatives: radical surgical treatment, external beam radiotherapy or brachytherapy. However, whole-gland treatment induces significant morbidity and burden on quality of life. Targeted treatments of the index tumor are currently under investigation to decrease morbidity while proposing active treatment.
The purpose of this study is to assess the efficacy of a novel ablation treatment using microwaves, delivered transrectally or transperineally under real-time guidance with MRI-transrectal ultrasound image registration. The index tumor will be detected with prostate MRI and characterized with targeted biopsies using Organ Based Tracking (OBT) fusion with the TRINITY system (KOELIS, Meylan, France). The same system will be used to identify the index lesion and guide the targeted microwave ablation performed with the TATO3 device (Biomedical Srl, Florence, Italy).
All patients will undergo biopsy at 12 months of follow-up. A biopsy session will also be performed at 6 months, but only for patients with imaging results suspicious for cancer within the ablated area on the mpMRI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient diagnosed with an intermediate-risk prostate cancer, defined by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Targeted microwave transrectal or transperineal ablation of the prostatic index tumor using MRI-transrectal image registration and OBT fusion
Device: Targeted microwave ablation
Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach
The proportion of patients with no evidence of cancer on targeted biopsy
The proportion of patients with no evidence of cancer on targeted biopsy at 12 months, defined by a minimum of 2 targeted core biopsies taken from the index tumor site treated with microwave ablation for focal treatment of intermediate risk prostate cancer
Time frame: 12 months
Proportion of radical salvage treatment
Proportion of patients undergoing radical salvage treatment of the index lesion
Time frame: 12 months
Time to radical salvage treatment
Time to radical salvage treatment of the index lesion
Time frame: 12 months
Proportion of patients with any cancer in the untreated area
Proportion of patients with any cancer in the untreated area, determined by a minimum 12 cores systematic biopsy
Time frame: 12 months
Proportion of patients undergoing treatment for cancer in the untreated area
Proportion of patients undergoing treatment for cancer in the untreated area and time to treatment
Time frame: 12 months
IPSS questionnaire
Changes in patients' reported outcome measures (PROMs) for urinary symptoms using IPSS score compared to baseline, score ranging from 0 to 35 (the higher the worse)
Time frame: 7 days and 1, 6 and 12 months
IIEF-5 questionnaire
Changes in patients' reported outcome measures (PROMs) for erectile function using IIEF-5 score compared to baseline, score ranging from 5 to 25 (the lower the worse)
Time frame: 7 days and 1, 6 and 12 months
MSHQ-EjD-SF questionnaire
Changes in patients' reported outcome measures (PROMs) for ejaculatory function and bother using MSHQ-EjD-SF score compared to baseline, score ranging from 1 to 15 (the lower the worse) for ejaculatory function and from 0 to 5 for bother/satisfaction (the higher the worse)
Time frame: 7 days and 1, 6 and 12 months
Urine flow
Change in urine flow, using a uroflowmeter compared to baseline
Time frame: 7 days and 1, 6 and 12 months
Adverse events
Number and severity of device and procedure related adverse events
Time frame: 12 months
Patient post-operative pain level
Average patient post-operative pain level reported on a pain numeric rating scale, with a range from 0 (no pain) to 10 (worst pain ever)
Time frame: Treatment day-evaluated between 2 and 4 hours after the procedure
Patient satisfaction
Patient satisfaction with the microwave ablation procedure as determined by questionnaire (no score assigned)
Time frame: 1, 6 and 12 months
Ease of the procedure
Ease of the procedure measured with a score chosen by the operator (1: easy, 2: moderate, 3: difficult)
Time frame: Day 1
Duration of the procedure and associated variables
Duration of the procedure and associated variables
Time frame: Day 1
PSA
Change in PSA measurement compared to baseline
Time frame: 1, 3, 6, 9 and 12 months
PSA Nadir
Time to PSA Nadir after treatment of the index lesion
Time frame: 12 months
Prostate volume
Change in volume of the prostate on the mpMRI compared to baseline
Time frame: 7 days and 6 and 12 months
Patient motivation
Characterization of patient motivation to undergo targeted microwave ablation for treatment of the index lesion, as assessed by patient questionnaire (no score assigned)
Time frame: Baseline
Surgeon opinion regarding adequate guidance of the microwave ablation needle
To evaluate the adequate guidance of the microwave ablation needle by the surgeon opinion
Time frame: Day 1
Adequate guidance of the microwave ablation needle on the treated index lesion
To evaluate the adequate guidance of the microwave ablation needle by percentage of covering of the treated index lesion
Time frame: Day 1
Adequate guidance of the microwave ablation needle on the treated index lesion and margins
To evaluate the adequate guidance of the microwave ablation needle by percentage of covering of the treated index lesion and margins
Time frame: Day 1
Learning curve of the TMA procedure
To evaluate the learning curve of the TMA procedure by the duration of the intervention (delay between probe in and the end of anesthesia (minutes).
Time frame: Day 1
Plan to share: No
Ran from Feb 2021 to primary completion in Jul 2025, 53 months.
Of 58 industry-sponsored interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's 53 months is above that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Koelis